SK Bioscience recorded an operating loss in the mid-KRW 15.7 billion range on a consolidated basis in the second quarter of this year, but significantly narrowed its deficit compared to the same period last year, continuing its trend of improving performance.

According to a regulatory filing on the 10th, SK Bioscience's preliminary consolidated revenue for the second quarter of 2026 was tallied at KRW 155.705 billion. This represents a decrease of 7.7% from the previous quarter (KRW 168.611 billion) and 3.8% from the same period last year (KRW 161.86 billion).

Meanwhile, the second-quarter operating loss stood at KRW 15.738 billion, a reduction in deficit compared to both the previous quarter (KRW 44.535 billion) and the same period last year (KRW 37.395 billion). The filing showed improvement rates of 64.7% and 57.9%, respectively.

Loss before income tax from continuing operations also narrowed to KRW 16.437 billion, compared to KRW 47.846 billion in the previous quarter and KRW 35.163 billion in the same period last year. Net loss for the period decreased to KRW 14.086 billion, down from KRW 36.164 billion in the previous quarter and KRW 16.779 billion a year earlier. However, net loss attributable to owners of the parent company was KRW 17.888 billion, a decrease from the previous quarter (KRW 33.327 billion) but an expansion compared to the same period last year (KRW 16.476 billion).

Cumulative revenue for the first half of this year totaled KRW 324.316 billion, up 2.5% from KRW 316.417 billion in the same period last year. However, the cumulative operating loss for the first half widened to KRW 60.273 billion from KRW 52.521 billion a year earlier, with a cumulative net loss of KRW 50.251 billion.

These preliminary performance figures are based on consolidated financial statements prepared in accordance with the Korean International Financial Reporting Standards (K-IFRS) and are subject to change following the external auditor's accounting review.